BIO vs. ONC: Bio-Rad Laboratories vs. BeOne Medicines Stock Comparison
How do Bio-Rad Laboratories (BIO) and BeOne Medicines (ONC) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Bio-Rad Laboratories (BIO) and BeOne Medicines (ONC) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO is classified in Life Sciences Tools & Services while ONC is classified in Biotechnology.
Bio-Rad Laboratories (BIO) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | BIO | ONC |
|---|---|---|
| Name | Bio-Rad Laboratories Inc. | BeOne Medicines Ltd. American Depositary Shares |
| Country/Region | United States | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| GICS Sub-Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 10.26 billion USD | 46.49 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | February 27, 1980 | February 3, 2016 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BIO | ONC |
|---|---|---|
| Total Return (1Y) | 28.31% | 30.59% |
| Total Return (3Y, Annualized) | 8.52% | 30.15% |
| Total Return (5Y, Annualized) | -11.74% | 2.48% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BIO | ONC |
|---|---|---|
| Volatility (1Y, Annualized) | 36.50% | 35.90% |
| Beta (5Y) | 1.03 | 0.59 |
| Max Drawdown (5Y) | -72.24% | -68.89% |
| Avg. Volume (3M) | 250.78K | 405.29K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BIO | ONC |
|---|---|---|
| Sharpe Ratio (1Y) | 0.66 | 0.73 |
| Sortino Ratio (1Y) | 0.98 | 1.15 |
Profitability
ROE (TTM)
Both Bio-Rad Laboratories (BIO) at 14.27% and BeOne Medicines (ONC) at 18.40% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.27%
- Max
- 109.18%
- BIO
- 14.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.40%
- Max
- 109.18%
- ONC
- 18.40%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Bio-Rad Laboratories (BIO) at 39.45% keeps the most of each sales dollar — above its industry’s net margin range — and BeOne Medicines (ONC) at 13.86% also retains a top-quartile share.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.45%
- BIO
- 39.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.86%
- Max
- 18.05%
- ONC
- 13.86%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
BeOne Medicines (ONC) at 22.15% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.82%
- Max
- 83.12%
- Q3
- 14.77%
- BIO
- 11.82%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.15%
- Max
- 83.12%
- ONC
- 22.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BIO | ONC |
|---|---|---|
| ROE (TTM) | 14.27% | 18.40% |
| ROA (TTM) | 1.50% | 8.42% |
| Net Margin (TTM) | 39.45% | 13.86% |
| Operating Margin (TTM) | 11.82% | 22.15% |
| Gross Margin (TTM) | 52.19% | 89.39% |
Growth
Revenue Growth
Both Bio-Rad Laboratories (BIO) at 0.65% and BeOne Medicines (ONC) at 40.23% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Neither Bio-Rad Laboratories (BIO) nor BeOne Medicines (ONC) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | BIO | ONC |
|---|---|---|
| Revenue Growth (YoY) | 0.65% | 40.23% |
| Revenue Growth (3Y CAGR) | -2.68% | 55.69% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Bio-Rad Laboratories (BIO) at 3.18 and BeOne Medicines (ONC) at 3.55 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.18
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- BIO
- 3.18
- Q1
- 2.47
- Min
- 0.10
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ONC
- 3.55
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Bio-Rad Laboratories (BIO) at 0.18 and BeOne Medicines (ONC) at 0.35 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.18
- Max
- 1.42
- Q3
- 0.65
- BIO
- 0.18
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.42
- Q3
- 0.65
- ONC
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BIO | ONC |
|---|---|---|
| Current Ratio (MRQ) | 3.18 | 3.55 |
| Debt / Equity (MRQ) | 0.18 | 0.35 |
| Net Debt / EBITDA | -0.73 | -2.80 |
Dividends
Dividend Yield (TTM)
Neither Bio-Rad Laboratories (BIO) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Bio-Rad Laboratories (BIO) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BIO | ONC |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while BeOne Medicines (ONC) at 52.17 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.14
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- BIO
- 10.14
- Min
- 0.07
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.17
- Max
- 85.34
- ONC
- 52.17
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Bio-Rad Laboratories (BIO) at 3.96 and BeOne Medicines (ONC) at 7.04 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.96
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIO
- 3.96
- Q1
- 3.01
- Min
- 0.01
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.04
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ONC
- 7.04
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Bio-Rad Laboratories (BIO) at 1.35 looks cheap against book in the lower P/B ratio quartile, while BeOne Medicines (ONC) at 7.98 carries a premium in the upper quartile — a clear price-to-book gap.
BIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BIO
- 1.35
- Min
- -5.59
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.98
- Max
- 13.53
- ONC
- 7.98
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BIO | ONC |
|---|---|---|
| P/E Ratio (TTM) | 10.14 | 52.17 |
| P/S Ratio (TTM) | 3.96 | 7.04 |
| P/B Ratio (MRQ) | 1.35 | 7.98 |
| Free Cash Flow Yield (TTM) | 2.65% | 2.21% |